Julio Chong, MD
Urology · Lafayette, CONPI 1881012722
Payments from drug & device makers
What this record shows
This record is dominated by grants: $25,000 of the $35,727 with a category attached, or 70.0%. Boston Scientific accounts for 82.4% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $26,836 and has fallen 90.2% since, to $2,635 in 2025. Among urology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $170.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$29K
- Teleflex LLC$2K
- Medtronic$600
- Calyxo, Inc.$589
- Johnson & Johnson$368
- Astellas Pharma US Inc$284
- plus $3K from 35 others
What the payments were for
- Consulting fees$6002%
- Grants$25,00070%
- Travel & lodging$2,1536%
- Food & beverage$7,75422%
- Education$2201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 67 | $29,436 |
| Teleflex LLC | 22 | $1,844 |
| Medtronic | 1 | $600 |
| Calyxo, Inc. | 6 | $589 |
| Johnson & Johnson | 6 | $368 |
| Astellas Pharma US Inc | 7 | $284 |
| Sumitomo Pharma America, Inc. | 13 | $277 |
| Pfizer | 6 | $214 |
| KARL Storz Endoscopy-america | 3 | $172 |
| Antares Pharma, Inc. | 8 | $168 |
| AbbVie | 8 | $154 |
| Cook Medical LLC | 1 | $143 |
| Myriad Genetic Laboratories, Inc. | 5 | $133 |
| Endo Pharmaceuticals Inc. | 4 | $132 |
| Travere Therapeutics, Inc. | 2 | $131 |
| Olympus America Inc. | 4 | $100 |
| Ferring Pharmaceuticals Inc. | 5 | $98 |
| Axonics, Inc. | 4 | $86 |
| Myovant Sciences Inc. | 4 | $84 |
| Bayer | 3 | $77 |
| Convatec Inc. | 4 | $77 |
| Telix Pharmaceuticals | 3 | $58 |
| Progenics Pharmaceuticals, Inc. | 2 | $52 |
| Novo Nordisk | 3 | $52 |
| Laborie Medical Technologies Corp. | 2 | $41 |
| Blue Earth Diagnostics | 1 | $39 |
| 180 Medical, Inc. | 1 | $32 |
| Baxter Healthcare | 1 | $26 |
| Immunitybio, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| AstraZeneca | 1 | $23 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Urovant Sciences Inc | 1 | $22 |
| Coloplast | 1 | $21 |
| Steris Corporation | 1 | $21 |
| BD | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Dendreon Pharmaceuticals LLC | 1 | $18 |
| ABC Home Medical Supply, Inc. | 1 | $15 |
| Dentsply IH AB | 1 | $14 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$26,242
- UroLift System$1,129
- GENERAL BPH$590
- CVAC Aspiration System$527
- LithoVue$486
- UroLift$460
- Erleada$268
- SWISS LITHOCLAST TRILOGY$245
- Cook Medical Perc Sets$143
- AMS$142
- 09 PROMO FLEX-X FLEX URETEROSCOPE, 7.5F$140
- LITHOCLAST$139
- Lumenis Pulse 100H$132
- XTANDI$125
- SpaceOAR VUE System - 10mL$119
- (815) Thiola$114
How this compares
$35,727 in reported general payments places this provider in the 90th percentile of 225 urology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 74 | $58,635 |
| OrgovyxRelugolix | 12 | $29,954 |
| Potassium Citrate ErPotassium Citrate | 79 | $6,677 |
| Methenamine Hippurate | 41 | $4,040 |
| Tamsulosin Hcl | 179 | $1,225 |
| Estradiol | 16 | $1,069 |
| Solifenacin Succinate | 20 | $593 |
| Oxybutynin Chloride ErOxybutynin Chloride | 69 | $557 |
| Cefdinir | 58 | $528 |
| Oxycodone Hcl | 65 | $261 |
| Promethazine Hcl | 22 | $230 |
| Ondansetron OdtOndansetron | 17 | $182 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $167 |
| Ciprofloxacin Hcl | 18 | $151 |
| CefuroximeCefuroxime Axetil | 12 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $284 | $58,63574 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $277 | $29,95412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 urology providers in Colorado.
Other urology in Lafayette
- Alexandra RogersLafayette$476K
- Lawrence KarshDenver$706K
- Derek ZukoskyGolden$442K
- James McBrideDurango$234K
- Damian SorceParker$224K
- Suzanne MerrillLone Tree$102K
- Ali SarramLone Tree$76K
- John KeferBoulder$68K
- Garrick GreearLongmont$62K
- Nicholas WestfallGrand Junction$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.